Subcutaneous teicoplanin in staphylococcal bone and joint infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Orthopedics

Background:

• Staphylococcal bone and joint infections require effective antibiotic treatment.
• Teicoplanin is an effective antibiotic, but administration routes can be challenging.
• Subcutaneous administration offers a potential alternative for teicoplanin delivery.

Purpose of the Study:

• To evaluate the efficacy and safety of subcutaneous teicoplanin.
• To describe its use as an alternative treatment for staphylococcal bone and joint infections.

Main Methods:

• Retrospective multicentric cohort study.
• Inclusion of patients with staphylococcal bone and joint infections treated with subcutaneous teicoplanin.
• Analysis of patient data from 2002 to 2015.

Main Results:

• Forty patients were assessed in the cohort.
• Subcutaneous teicoplanin administration showed no excess risk of treatment failure.
• Trough levels were comparable across routes and increased with higher loading doses (≥9 mg/kg/injection).

Conclusions:

• Subcutaneous teicoplanin is an acceptable alternative for treating staphylococcal bone and joint infections.
• This route offers flexibility in antibiotic administration.
• Further research may explore optimal dosing for subcutaneous teicoplanin.